Rising Incidences of the Cancer Cases, Followed by Growing Awareness to Drive the Cancer Screening Market in North American Region: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Cancer screening means to perceive cancer before symptoms appear. It includes urine tests, blood tests, DNA tests and other tests or medical imaging. It is classified into many types such as cervical cancer screening, prostate cancer screening, breast cancer screening, colorectal cancer screening, head & neck cancer screening, liver cancer, mouth cancer, abdominal cancer, lung cancer screening, thyroid cancer, testicular cancer, pancreatic cancer, and genetic cancer screening. Breast cancer is common cancer in females, in both urbanized and underdeveloped countries. The major screening tests are Pap smear (for cervical cancer) & human papillomavirus (HPV) tests, sigmoidoscopy, cancer antigen 125 (CA-125)tests, alpha-fetoprotein blood test, colonoscopy (colon cancer), low-dose helical computed tomography, Prostate-specific antigen (PSA test),transvaginal ultrasound and mammography (breast cancer). According to study, “North America Cancer Screening Market (2018-2023)” some of the major companies that are currently operating in the North American cancer screening market are GE Healthcare, Thermo Fisher Scientific, Abbott Diagnostics, Siemens Healthcare GmbH, Roche Diagnostics, Qiagen, Hologic Inc. All these key players are concentrating on research & development (R&D) and incoming into associations with the government to enlarge regional access. On the basis of type, the North America cancer screening market is segmented into breast Magnetic Resonance Imaging (MRI) Screening, mammography screening, and breast ultrasound screening. On the basis of technique type, the market is segmented into genetic, laboratory, biopsy, imaging, and endoscopy tests. Genetic tests include Next Generation Sequencing (NGS), biomarker testing and microarray techniques. Biopsy & cytology test includes CT-guided biopsy, bone marrow biopsy, needle biopsy, bone biopsy, surgical biopsy, and aspiration biopsy. Imaging techniques are sub-segmented into nuclear, mammography and ultrasound and many others. On the basis of the stage, the market is segmented into TNM stages, stages (0-4), prognostic factors and other staging systems. In addition, on the basis of end-user, the market is segmented into laboratories & independent physicians, hospitals, and clinics. The National Cancer Institute (NCI) maintenances research, health information dissemination, training, and other activities associated with the causes, diagnosis, prevention, and treatment of cancer. In addition, Cancer Intervention and Surveillance Modeling Network (CISNET) is an association of NCI that use numerical modeling to improve understanding of cancer control interventions. Some of the key benefits associated are less radical treatment needed, better outcome, reduced mortality & morbidity, cost savings, identification of high-risk groups & opportunities for intervention, improved prognosis, and many others. Apart from the advantages some of the major disadvantages are over the treatment of borderline abnormalities, resource costs of screening system and longer morbidity. Moreover, there are some of the risks associated unnecessary distress, increased testing, radiation, missed a diagnosis, history of inflammatory bowel disease (IBS), sedentary lifestyles, obesity, Lynch syndrome, false positives, and over treatments. The cancer screening is driven by rising incidence of cancer cases, followed by growing awareness early recognition of breast cancer, rising technological advancements, increasing aging population followed the rise in funds for cancer treatment by the government. However, lack of transparency in medical procedures, lack of associated funding and stringent government regulations and many others. During 2018-2023, the North America cancer screening market is anticipated to grow at a CAGR of 11.1% subsequent in annual proceeds of US$ 16.3 billion. In the upcoming years, it is estimated that the market to grow fast due to the rise in technological advancements and the growing incidence of cancer cases. To know more, click on the link below:- https://www.kenresearch.com/healthcare/medical-devices/north-america-cancer/172429-91.html Related Reports:- https://www.kenresearch.com/healthcare/medical-devices/global-cancer-screening/172430-91.html https://www.kenresearch.com/healthcare/medical-devices/europe-cancer-screening/172426-91.html Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Sales@kenresearch.com +91-9015378249 Tags: Cancer Screening Industry in North America, Cancer Screening Market in North America, North America Cancer Diagnostics Market Analysis, North America Cancer Screening Industry Research Report, North America Cancer Screening Market Future outlook, North America Cancer Screening Market Growth Forecast, North America Cancer Screening Market Major Players, North America Cancer Screening Market Overview, North America Cancer Screening Market Research Report, North America Cancer Screening Market Scope, North America Cancer Screening Market Segmentation